Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENIA study of AZD4144 in sepsis-associated acute kidney injury
2025-522232-13-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in sepsis-associated acute kidney injury (S-AKI) comparing AZD4144 with Placebo for AZD4144 (2 arms). Primary endpoint: Area under the curve of 24-hour creatinine clearance. Planned start Mar 2026; status: authorised.
02
Drugs
AZD4144
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on 2025-522232-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522232-13-00.